Charles River Laboratories International, Inc. $CRL Shares Bought by Prudential Financial Inc.

Prudential Financial Inc. increased its position in Charles River Laboratories International, Inc. (NYSE:CRL) by 39.7% in the 2nd quarter, HoldingsChannel reports. The institutional investor owned 38,404 shares of the medical research company’s stock after acquiring an additional 10,912 shares during the period. Prudential Financial Inc.’s holdings in Charles River Laboratories International were worth $5,827,000 at the end of the most recent reporting period.

Several other large investors have also bought and sold shares of CRL. Coldstream Capital Management Inc. raised its position in Charles River Laboratories International by 11.8% in the second quarter. Coldstream Capital Management Inc. now owns 1,918 shares of the medical research company’s stock worth $291,000 after acquiring an additional 203 shares in the last quarter. American Century Companies Inc. boosted its position in shares of Charles River Laboratories International by 41.9% during the 2nd quarter. American Century Companies Inc. now owns 5,469 shares of the medical research company’s stock valued at $830,000 after purchasing an additional 1,616 shares in the last quarter. Rhumbline Advisers grew its stake in shares of Charles River Laboratories International by 9.7% in the 2nd quarter. Rhumbline Advisers now owns 95,142 shares of the medical research company’s stock worth $14,436,000 after purchasing an additional 8,412 shares during the last quarter. Mufg Securities Americas Inc. raised its holdings in shares of Charles River Laboratories International by 20.1% in the 2nd quarter. Mufg Securities Americas Inc. now owns 1,088 shares of the medical research company’s stock worth $165,000 after purchasing an additional 182 shares in the last quarter. Finally, Legal & General Group Plc lifted its stake in Charles River Laboratories International by 12.3% during the second quarter. Legal & General Group Plc now owns 106,201 shares of the medical research company’s stock valued at $16,114,000 after purchasing an additional 11,614 shares during the last quarter. Institutional investors own 98.91% of the company’s stock.

Wall Street Analyst Weigh In

Several research analysts have issued reports on the stock. Argus set a $200.00 price target on shares of Charles River Laboratories International in a research report on Monday, November 17th. Wall Street Zen cut Charles River Laboratories International from a “buy” rating to a “hold” rating in a report on Saturday, November 8th. Robert W. Baird raised Charles River Laboratories International from a “neutral” rating to an “outperform” rating and boosted their target price for the stock from $178.00 to $199.00 in a research report on Thursday, November 6th. Barclays upped their target price on Charles River Laboratories International from $195.00 to $210.00 and gave the company an “overweight” rating in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. lifted their price target on Charles River Laboratories International from $160.00 to $165.00 and gave the stock a “neutral” rating in a research note on Thursday, November 6th. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus target price of $190.86.

Charles River Laboratories International Trading Down 0.4%

Shares of NYSE CRL opened at $178.14 on Friday. Charles River Laboratories International, Inc. has a one year low of $91.86 and a one year high of $203.01. The firm has a market capitalization of $8.77 billion, a PE ratio of -133.94, a PEG ratio of 4.83 and a beta of 1.53. The company has a current ratio of 1.36, a quick ratio of 1.10 and a debt-to-equity ratio of 0.69. The business has a 50-day moving average price of $171.68 and a two-hundred day moving average price of $160.16.

Charles River Laboratories International (NYSE:CRL) last issued its earnings results on Wednesday, November 5th. The medical research company reported $2.43 earnings per share for the quarter, beating analysts’ consensus estimates of $2.32 by $0.11. The company had revenue of $1 billion for the quarter, compared to the consensus estimate of $990.43 million. Charles River Laboratories International had a positive return on equity of 15.74% and a negative net margin of 1.69%.The firm’s quarterly revenue was down .5% on a year-over-year basis. During the same quarter in the prior year, the company earned $2.59 EPS. As a group, analysts predict that Charles River Laboratories International, Inc. will post 9.36 earnings per share for the current fiscal year.

About Charles River Laboratories International

Charles River Laboratories International, Inc provides drug discovery, non-clinical development, and safety testing services in the United States, Europe, Canada, the Asia Pacific, and internationally. It operates through three segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing).